BIO-TECHNE Corp 4

SVP - General Counsel Shane Bohnen received awards of 11,344 time-based RSUs and 18,432 performance-based RSUs of Bio-Techne Corp common stock on August 17, 2026.

On August 17, 2026, Shane Bohnen, SVP - General Counsel of Bio-Techne Corp, received significant new equity compensation in the form of restricted stock units (RSUs). The Form 4 reflects prior grants of stock options and performance RSUs, then discloses two new RSU awards: 11,344 time-based RSUs and 18,432 performance-based RSUs, each convertible into an equal number of common shares upon vesting. No shares were purchased or sold for cash; the transactions are purely awards of equity intended as long-term incentive compensation. After these grants, Bohnen’s beneficial ownership includes a mix of vested and unvested stock options, performance RSUs, and time-based RSUs across multiple future vesting dates, aligning his incentives with the company’s long-term performance.

Filing Facts

CIK

842023

Ticker

TECH

Form

4

Source Type

fda

Accession

0000914190-26-000134

Alert Tier

5